A new research letter published in JAMA Internal Medicine found substantial variation among 17 “top-performing” hospitals—14 of them enrolled in 340B—in what they charge commercial insurers for clinician-administered drugs.
Meanwhile, new research published in Journal of Healthcare Quality found that a health center’s hepatitis C virus (HVC) screening initiative improved screening rates significantly during the eight-month-long study. “The 340B Drug Pricing Program can provide a financially sustainable method of providing HCV treatment,” the researchers said.
A new research letter published in JAMA Internal Medicine found substantial variation among 17 “top-performing” hospitals—14 of them enrolled in 340B—in what they charge commercial insurers for clinician-administered drugs.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.